Transplant Survival and Transplant Living
Liver transplantation has been accepted as a life-saving treatment and standard of care for many forms of end-stage liver disease since the early 1980. Liver transplants used deceased donor livers. If a liver transplant candidate is eligible to receive from a living donor, then a family member, relative or close friend can be considered for donation. Living donor transplantation proposals and another to waiting for a deceased-donor organ to become available for people in need of an organ transplant. In addition, living-donor organ transplants. As associated with less complications than deceased-donor transplants and, overall, a longer survival of the donor organ.
Related Conference of Transplant Survival and Transplant Living
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
Transplant Survival and Transplant Living Conference Speakers
Recommended Sessions
- Cyclosporine
- Drug Delivery in Transplantation
- Heart transplant
- Immunosuppressant
- Kaposi Sarcoma in case of solid organ transplantation
- Kidney transplant
- Lung transplant
- Medicine - Surgery
- Organ Donation
- Organ Rejection
- Organ Transplantation
- Organ Transplantation Market to Ascent Exponentially
- Skin & Tissue Grafting
- Stem Cell Transplantation
- Transplant Survival and Transplant Living
- Transplantation Special legal and Ethical problems
- Trends in Organ Transplantation
Related Journals
Are you interested in
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)

